Key facts
- Notable investors include StartX (US), Mohammed Bin Rashid Innovation Fund, Astana Hub, Gitex Europe, Google Accelerator — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ARLAN BIOTECH
- ·The full record, as it builds
Funding rounds
No funding rounds for ARLAN BIOTECH are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ARLAN BIOTECH
Developer of a generative artificial intelligence tool designed to accelerate the discovery and development of antibodies. The company's platform uses proprietary algorithms to generate target-specific antibody sequences and reduce reliance on traditional discovery methods, enabling researchers to create antibodies against a wide range of protein targets with greater speed and efficiency.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2014
- Employees
- 6
- Website
- arlanbiotech.com/
- Ownership
- Privately Held (backing)
ARLAN BIOTECH doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ARLAN BIOTECH shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ARLAN BIOTECH in its N-PORT filings yet. We sweep new filings monthly.